WHO ICTRP trial

An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral…

TCTR20210521001 · Thai Clinical Trials Registry (TCTR) · Not Recruiting

Key facts

Trial ID TCTR20210521001
Public title An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover BE Study of Rozacor (20 mg) of The Government Pharmaceutical Organization, Thailand with CRESTOR of IPR Pharmaceuticals Inc., Puerto Rico, in Healthy Human Subjects under Fasting Conditions
Scientific title An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover BE Study of Rozacor (20 mg) of The Government Pharmaceutical Organization, Thailand with CRESTOR of IPR Pharmaceuticals Inc., Puerto Rico, in Normal, Healthy, Adults Human Subjects under Fasting…
Primary sponsor The Government Pharmaceutical Organization
Registry Thai Clinical Trials Registry (TCTR)
Recruitment status Not Recruiting
Study type Interventional
Phase Phase 1
Countries Thailand
Conditions Healthy male and female subjects Healthy male and female subjects Bioequivalence fed conditions;Healthy male and female subjects Bioequivalence fed conditions
Interventions Each tablet contains rosuvastatin calcium equivalent to 20 mg of rosuvastatin ,Each tablet contains rosuvastatin calcium equivalent to 20 mg of rosuvastatin;Active Comparator Drug,Experimental Drug;CRESTOR,ROZACOR (20 mg)
Registration date May 21, 2021
Target size 50
Secondary IDs Nil Known
Registry page thaiclinicaltrials.org

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations